相关实验视频

Updated: Jun 22, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

一种基于IgG的表皮生长因子受体向免疫毒素,对抗头癌具有强大的抗瘤活性

Mei Huang¹, Jisoo Park², Jina Seo²

¹Department of Medical Sciences, Graduate School of Ajou University, Suwon, Republic of Korea.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

|July 1, 2024

概括

一种新的EGFR向免疫毒素CTX-LR-LO10被开发用于克服头癌的耐药性. 这种新疗法在临床前模型中显示出显著的瘤抑制,为EGFR阳性癌症提供了一个有希望的替代方案.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
分子生物学分子生物学

背景情况:

表皮生长因子受体 (EGFR) 是头癌 (HNC) 治疗的关键标.
现有的抗EGFR疗法由于耐药性而面临限制.
对于EGFR阳性的HNC,有必要制定替代治疗策略.

研究的目的:

开发一种针对EGFR的新型免疫毒素CTX-LR-LO10,以克服耐药性.
在HNC模型中评估CTX-LR-LO10的疗效和作用机制.
探索CTX-LR-LO10作为一种潜在的新疗法剂.

主要方法:

通过使用特定位点的结合,通过将 cetuximab (CTX) 与 Pseudomonas exotoxin A 片段 (LR-LO10) 结合,开发出一种免疫毒素 (CTX-LR-LO10).
评估了CTX-LR-LO10.10的结合亲和力,稳定性,免疫细胞相互作用和药理动力学.
在实验室对EGFR阳性HNC细胞 (蛋白质合成抑制,亡,迁移,入侵) 的评估.
在异种移植小鼠模型中进行了体内疗效测试.
进行了转录组分析,以了解免疫反应和基因表达变化.

主要成果:

CTX-LR-LO10表现出与EGFR的特定结合,并保留了IgG的特性.
免疫毒素抑制了蛋白质合成和诱导的亡,减少了HNC细胞的迁移和入侵.
与CTX或LR-LO10相比,CTX-LR-LO10在小鼠模型中显示出优异的瘤抑制.
转录组分析表明免疫反应激活和与其机制相关的改变基因表达.

结论:

CTX-LR-LO10是一种强大的EGFR向免疫毒素,具有显著的临床前疗效.
这种新型免疫毒素克服了现有疗法的局限性,需要进一步研究.
CTX-LR-LO10代表了对EGFR阳性癌症的有前途的新疗法候选者.

关键词:

抗体 - 药物结合物结合物这就是 cetuximab 的意思.皮肤上生长因子受体.头部和部癌症头部和部癌症免疫毒素是一种免疫毒素.定向的照片交叉链接.

更多相关视频

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...